All Stories

  1. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin

    Article • Clinical Pharmacology & Therapeutics, March 2024, Wiley

    Dr Marcus Hompesch

  2. Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions

    Article • Journal of Hepatology, October 2023, Elsevier

    Dr Marcus Hompesch

  3. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long‐acting glucagon analogue HM15136 in overweight and obese patients with co‐morbidities

    Article • Diabetes Obesity and Metabolism, June 2023, Wiley

    Dr Marcus Hompesch

  4. A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer

    Article • Clinical Pharmacology & Therapeutics, May 2022, Wiley

    Dr Marcus Hompesch

  5. Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

    Article • Endocrinology Diabetes & Metabolism, April 2022, Wiley

    Dr Marcus Hompesch

  6. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

    Article • BMJ Open Diabetes Research & Care, January 2022, BMJ

    Dr Marcus Hompesch

  7. Author response for "Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin ( rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U / mL and 100 U / mL concentrate diluted to 1 U / mL in healthy males"

    Article • July 2021, Wiley

    Dr Marcus Hompesch

  8. 766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)

    Article • Diabetes, June 2021, American Diabetes Association

    Dr Marcus Hompesch

  9. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study

    Article • BMJ Open Diabetes Research & Care, June 2021, BMJ

    Dr Marcus Hompesch

  10. Author response for "Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin ( rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U / mL and 100 U / mL concentrate diluted to 1 U / mL in healthy males"

    Article • May 2021, Wiley

    Dr Marcus Hompesch

  11. Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients

    Article • Endocrinology Diabetes & Metabolism, February 2021, Wiley

    Dr Marcus Hompesch

  12. Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase random...

    Article • Diabetes Obesity and Metabolism, December 2020, Wiley

    Dr Marcus Hompesch

  13. Author response for "Inhibition of fatty acid synthase with <scp>FT</scp> ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with <scp>NAFLD</scp> non‐alcoholic fatty liver disease: results from two...

    Article • November 2020, Wiley

    Dr Marcus Hompesch

  14. 107-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects (HS)

    Article • Diabetes, June 2020, American Diabetes Association

    Dr Marcus Hompesch

  15. Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes

    Article • Diabetes Obesity and Metabolism, April 2020, Wiley

    Dr Marcus Hompesch

  16. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

    Article • Diabetes Obesity and Metabolism, August 2019, Wiley

    Dr Marcus Hompesch

  17. 1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

    Article • Diabetes, June 2019, American Diabetes Association

    Dr Marcus Hompesch

  18. 53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

    Article • Diabetes, June 2019, American Diabetes Association

    Dr Marcus Hompesch

  19. OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

    Article • Journal of the Endocrine Society, April 2019, Endocrine Society

    Dr Marcus Hompesch

  20. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

    Article • Postgraduate Medicine, February 2019, Taylor & Francis

    Geremia Bolli, Dr Marcus Hompesch

  21. Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins

    Article • January 2019, Springer Science + Business Media

    Dr Marcus Hompesch

  22. Quantification of Insulin Action in Human Subjects

    Article • January 2019, Springer Science + Business Media

    Dr Marcus Hompesch

  23. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease

    Article • January 2019, Springer Science + Business Media

    Dr Marcus Hompesch

  24. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study

    Article • Diabetes Care, September 2018, American Diabetes Association

    Dr Marcus Hompesch

  25. Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon–Like Peptide–1 Receptor Agonist (GLP–1RA)–Evidence from Preclinical, Modeling, and Clinical Studies

    Article • Diabetes, July 2018, American Diabetes Association

    Dr Marcus Hompesch

  26. In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists

    Article • Diabetes, July 2018, American Diabetes Association

    Dr Marcus Hompesch

  27. Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

    Article • Diabetes, July 2018, American Diabetes Association

    Dr Marcus Hompesch

  28. The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes

    Article • Diabetes, July 2018, American Diabetes Association

    Dr Marcus Hompesch

  29. Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research

    Article • Biomarkers in Medicine, November 2016, Future Medicine

    Dr Marcus Hompesch

  30. Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin

    Article • Journal of Diabetes Science and Technology, July 2016, SAGE Publications

    Dr Marcus Hompesch

  31. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial

    Article • Diabetes Obesity and Metabolism, June 2016, Wiley

    Dr Marcus Hompesch

  32. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles

    Article • Diabetes Obesity and Metabolism, April 2016, Wiley

    Dr Marcus Hompesch

  33. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. A Focus on Early Phase Clinical Studies. Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch (eds) Springer 2015, ISBN 978-1-4471-4919-4.

    Article • Diabetes Obesity and Metabolism, April 2016, Wiley

    Dr Marcus Hompesch

  34. Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch (Eds). Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development: A Focus on Early Phase Clinical Studies

    Article • Pharmaceutical Medicine, April 2016, Springer Science + Business Media

    Dr Marcus Hompesch

  35. Considerations in biosimilar insulin device development

    Article • Biosimilars, February 2016, Dove Medical Press

    Dr Marcus Hompesch

  36. Biosimilar insulins: current and future perspectives

    Article • Diabetes Management, November 2015, OMICS Publishing Group

    Dr Marcus Hompesch

  37. Biosimilar insulins: guidance for data interpretation by clinicians and users

    Article • Diabetes Obesity and Metabolism, July 2015, Wiley

    Dr Marcus Hompesch

  38. Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide

    Article • Drugs, May 2015, Springer Science + Business Media

    Dr Marcus Hompesch

  39. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action

    Article • Journal of Diabetes, March 2015, Wiley

    Dr Marcus Hompesch

  40. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development

    Article • January 2015, Springer Science + Business Media

    Dr Marcus Hompesch

  41. Assessment of β-Cell Function

    Article • November 2014, Springer Science + Business Media

    Dr Marcus Hompesch

  42. Methods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles

    Article • November 2014, Springer Science + Business Media

    Dr Marcus Hompesch

  43. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

    Article • Diabetes Obesity and Metabolism, October 2014, Wiley

    Dr Marcus Hompesch

  44. Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

    Article • PLoS ONE, September 2014, PLOS

    Dr Marcus Hompesch

  45. Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

    Article • PLoS ONE, August 2014, PLOS

    Dr Marcus Hompesch

  46. Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects. Diabetes Care 2011;34:2496–2501

    Article • Diabetes Care, July 2014, American Diabetes Association

    Dr Marcus Hompesch

  47. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin

    Article • Diabetes Obesity and Metabolism, July 2014, Wiley

    Dr Marcus Hompesch

  48. Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

    Article • Diabetes Obesity and Metabolism, June 2014, Wiley

    Dr Marcus Hompesch

  49. Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?

    Article • Pharmaceutical Medicine, May 2014, Springer Science + Business Media

    Dr Marcus Hompesch

  50. LY2605541 (LY) exhibits a Flatter Glucodynamic profile than insulin Glargine (GL) at steady state in subjects with Type 1 Diabetes (T1D)

    Article • Diabetologie und Stoffwechsel, May 2014, Thieme Publishing Group

    Dr Marcus Hompesch

  51. Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

    Article • Clinical Therapeutics, April 2014, Elsevier

    Dr Marcus Hompesch

  52. Biosimilar Insulins

    Article • Journal of Diabetes Science and Technology, January 2014, SAGE Publications

    Dr Marcus Hompesch

  53. Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?

    Article • Drugs, October 2013, Springer Science + Business Media

    Dr Marcus Hompesch

  54. Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

    Article • Diabetes Care, June 2013, American Diabetes Association

    Dr Marcus Hompesch

  55. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

    Article • BMC Pharmacology and Toxicology, May 2013, Springer Science + Business Media

    Dr Marcus Hompesch

  56. Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase

    Article • Diabetes Care, October 2012, American Diabetes Association

    Dr Marcus Hompesch

  57. Developing New Drugs for Diabetes and Cardiometabolic Disorders

    Article • Drugs, September 2012, Springer Science + Business Media

    Dr Marcus Hompesch

  58. Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2012, Endocrine Society

    Dr Marcus Hompesch

  59. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

    Article • Diabetes Obesity and Metabolism, July 2012, Wiley

    Dr Marcus Hompesch

  60. Rapid Glycometabolic Improvement in Type 2 Diabetic (T2D) Patients with an ADA Isocaloric Diet Over a 22-Day Confinement in a Phase I Research Unit

    Article • Journal of Clinical Lipidology, May 2012, Elsevier

    Dr Marcus Hompesch

  61. Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase

    Article • Diabetes Technology & Therapeutics, March 2012, Mary Ann Liebert Inc

    Dr Marcus Hompesch

  62. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

    Article • Diabetes Obesity and Metabolism, February 2012, Wiley

    Dr Marcus Hompesch

  63. Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

    Article • Diabetes Care, October 2011, American Diabetes Association

    Dr Marcus Hompesch

  64. Reduction in Intrasubject Variability in the Pharmacokinetic Response to Insulin After Subcutaneous Co-Administration with Recombinant Human Hyaluronidase in Healthy Volunteers

    Article • Diabetes Technology & Therapeutics, October 2011, Mary Ann Liebert Inc

    Dr Marcus Hompesch

  65. Short-term metabolic effects of prednisone administration in healthy subjects

    Article • Diabetes Obesity and Metabolism, September 2011, Wiley

    Dr Marcus Hompesch

  66. Evaluation of a Novel Continuous Glucose Measurement Device in Patients with Diabetes Mellitus across the Glycemic Range

    Article • Journal of Diabetes Science and Technology, July 2011, SAGE Publications

    Dr Marcus Hompesch

  67. Biosimilar Insulins: How Similar is Similar?

    Article • Journal of Diabetes Science and Technology, May 2011, SAGE Publications

    Dr Marcus Hompesch

  68. Koadministration von Liraglutid mit Insulindetemir hat keinen Einfluss auf die Pharmakokinetik der beiden Arzneimittel

    Article • Diabetologie und Stoffwechsel, May 2011, Thieme Publishing Group

    Dr Marcus Hompesch

  69. Reduction of Postprandial Glycemic Excursions in Patients with Type 1 Diabetes: A Novel Human Insulin Formulation versus a Rapid-Acting Insulin Analog and Regular Human Insulin

    Article • Journal of Diabetes Science and Technology, May 2011, SAGE Publications

    Dr Marcus Hompesch

  70. Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Action than Subcutaneous Injection

    Article • Diabetes Technology & Therapeutics, April 2011, Mary Ann Liebert Inc

    Dr Marcus Hompesch

  71. Continuous Glucose Monitoring Using a Novel Glucose/Galactose Binding Protein: Results of a 12-Hour Feasibility Study with the Becton Dickinson Glucose/Galactose Binding Protein Sensor

    Article • Diabetes Technology & Therapeutics, March 2011, Mary Ann Liebert Inc

    Dr Marcus Hompesch

  72. Accelerated Insulin Pharmacokinetics and Improved Postprandial Glycemic Control in Patients With Type 1 Diabetes After Coadministration of Prandial Insulins With Hyaluronidase

    Article • Diabetes Care, January 2011, American Diabetes Association

    Dr Marcus Hompesch

  73. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

    Article • Diabetes Obesity and Metabolism, November 2010, Wiley

    Dr Marcus Hompesch

  74. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

    Article • May 2010

    Dr Marcus Hompesch

  75. Capillary and Venous Blood Glucose Concentrations Measured During Intravenous Insulin and Glucose Infusion: A Comparison of Steady and Dynamic States

    Article • Diabetes Technology & Therapeutics, October 2009, Mary Ann Liebert Inc

    Dr Marcus Hompesch

  76. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes

    Article • Current Medical Research and Opinion, September 2009, Informa Healthcare

    Dr Marcus Hompesch

  77. Glycemic Exposure Is Affected Favorably by Inhaled Human Insulin (Exubera) as Compared with Subcutaneous Insulin Glargine (Lantus) in Patients with Type 2 Diabetes

    Article • Diabetes Technology & Therapeutics, May 2009, Mary Ann Liebert Inc

    Dr Marcus Hompesch

  78. Evaluation of performance of a continuous glucose measurement device in subjects with type 1 and type 2 diabetes by means of a glucose clamp (hypoglycemia performance feasibility)

    Article • Canadian Journal of Diabetes, January 2009, Elsevier

    Dr Marcus Hompesch

  79. An Analysis of How to Measure Glucose during Glucose Clamps: Are Glucose Meters Ready for Research?

    Article • Journal of Diabetes Science and Technology, September 2008, SAGE Publications

    Dr Marcus Hompesch

  80. A novel insulin formulation with a more rapid onset of action

    Article • Diabetologia, July 2008, Springer Science + Business Media

    Dr Marcus Hompesch

  81. Role of Physicians in the Pharmaceutical Industry and Clinical Research Organizations: Take More Pride in Your Work

    Article • Journal of Diabetes Science and Technology, July 2008, SAGE Publications

    Dr Marcus Hompesch

  82. Intra-Individual Variability of the Metabolic Effect of a Novel Rapid-Acting Insulin (VIAject™) in Comparison to Regular Human Insulin

    Article • Journal of Diabetes Science and Technology, July 2008, SAGE Publications

    Dr Marcus Hompesch

  83. Die kurzwirksame Normalinsulinformulierung VIAject hat bei Patienten mit Typ-1-Diabetes ein breiteres therapeutisches Fenster bei der Dosisfindung als Normalinsulin

    Article • Diabetologie und Stoffwechsel, January 2008, Thieme Publishing Group

    Dr Marcus Hompesch

  84. Qualität der postprandialen Blutzuckereinstellung nach einer Testmahlzeit: Direkter Vergleich zwischen VIAject™ und Normalinsulin bei Patienten mit Typ 1 Diabetes

    Article • Diabetologie und Stoffwechsel, January 2007, Thieme Publishing Group

    Dr Marcus Hompesch

  85. Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes

    Article • Experimental and Clinical Endocrinology & Diabetes, September 2006, Thieme Publishing Group

    Dr Marcus Hompesch

  86. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

    Article • Diabetes Obesity and Metabolism, September 2006, Wiley

    Dr Marcus Hompesch

  87. Pharmakokinetische Eigenschaften einer neuartigen Normalinsulin-Formulierung

    Article • Diabetologie und Stoffwechsel, January 2006, Thieme Publishing Group

    Dr Marcus Hompesch

  88. Pharmacodynamic properties of Viaject™: A novel rapid-acting regular human insulin

    Article • Diabetologie und Stoffwechsel, January 2006, Thieme Publishing Group

    Dr Marcus Hompesch

  89. Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes

    Article • Diabetes Care, January 2005, American Diabetes Association

    Dr Marcus Hompesch

  90. Intrasubject Variability of Inhaled Insulin in Type 1 Diabetes: A Comparison with Subcutaneous Insulin

    Article • Diabetes Technology & Therapeutics, August 2004, Mary Ann Liebert Inc

    Dr Marcus Hompesch

  91.  -Lipoic Acid in NIDDM Patients With Cardiac Autonomic Neuropathy

    Article • Diabetes Care, December 1997, American Diabetes Association

    Dr Marcus Hompesch